Company: CRVO
Filing Date: 2025-07-28
Form Type: 8-K
Source: 0001437749-25-023646
Chunk: 1

Company: CervoMed Inc.
Filing Date: 2025-07-28
Form: 8-K
Item: Item 8.01
Chunk 1
---
Item 8.01

Other Events

The information set forth in the first paragraph and the information under the headings, “ New Data: 32-Week Results from the Extension Phase of the Phase 2b RewinD-LB Trial,” “ New Data: Reduction in Plasma Levels of Glial Fibrillary Acidic Protein at Week 32 of Extension Phase,” “ Previously Presented 16-Week Extension Phase Data,” and “ Old and New Capsules Have Similar Overall Safety and Tolerability Profile During Extension Phase,” of the Company’s press release referred to in Item 7.01 above is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

Item 9.01Financial Statements and Exhibits